Nexalin Technology (NXL) Change in Account Payables (2021 - 2026)
Nexalin Technology's (NXL) quarterly Change in Account Payables came in at -$76480.0 in Q1 2026, down 400.57% year-on-year from $25445.0 in Q1 2025, and down 142.49% quarter-over-quarter from $179996.0 in Q4 2025.
Nexalin Technology (NXL) Change in Account Payables (2021 - 2026) Analysis & Trends
Nexalin Technology's Change in Account Payables history runs 6 years deep, the most recent figure standing at -$76480.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables fell 400.57% year-over-year to -$76480.0 in Q1 2026; TTM through Mar 2026 was -$13296.0, a 144.49% decrease from a year earlier, with the FY2025 full-year figure at $88629.0, up 2572.22% from the prior year.
- Change in Account Payables declined to -$76480.0 in Q1 2026 per NXL's latest filing, from $179996.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $179996.0 in Q4 2025 and bottomed at -$353609.0 in Q1 2023.
- The 5-year median for Change in Account Payables is $3743.0 (2023), against an average of -$16257.4.
- Across the five-year window, Change in Account Payables plunged 1819.8% in 2024 and jumped 1799.2% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at -$139926.0 in 2022, then surged by 162.17% to $86985.0 in 2023, then plunged by 112.18% to -$10593.0 in 2024, then soared by 1799.2% to $179996.0 in 2025, then slumped by 142.49% to -$76480.0 in 2026.
- Per Business Quant, the three latest NXL Change in Account Payables figures stand at -$76480.0 (Q1 2026), $179996.0 (Q4 2025), and -$168228.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.39 Bn | 174.10 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.38 Bn | 125.50 Bn | 3.81 Bn | -198.00 Mn |
| 3 | Medtronic | 107.68 Bn | 98.46 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.98 Bn | 66.53 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 47.81 Bn | 44.13 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.53 Bn | 26.25 Bn | 1.98 Bn | 221.00 Mn |
| 7 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn | - |
| 8 | Smith & Nephew | 26.78 Bn | 26.20 Bn | - | - |
| 9 | Koninklijke Philips | 25.34 Bn | 22.21 Bn | 2.07 Bn | - |
| 10 | Nexalin Technology | 9.52 Mn | 6.81 Mn | 13,133.00 | -76,480.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76,480.00 |
| Mar 31, 2026 | -76,480.00 |
| Dec 31, 2025 | 179,996.00 |
| Dec 31, 2025 | 179,996.00 |
| Sep 30, 2025 | -168,228.00 |
| Sep 30, 2025 | -168,228.00 |
| Jun 30, 2025 | 51,416.00 |
| Jun 30, 2025 | 51,416.00 |
| Mar 31, 2025 | 25,445.00 |
| Mar 31, 2025 | 25,445.00 |
| Dec 31, 2024 | -10,593.00 |
| Dec 31, 2024 | -10,593.00 |
| Sep 30, 2024 | 79,404.00 |
| Sep 30, 2024 | 79,404.00 |
| Jun 30, 2024 | -64,372.00 |
| Jun 30, 2024 | -64,372.00 |
| Mar 31, 2024 | -8,024.00 |
| Mar 31, 2024 | -8,024.00 |
| Dec 31, 2023 | 86,985.00 |
| Dec 31, 2023 | 86,985.00 |